BMS ends Cellares pact over cell therapy production problems, triggering layoffs

PartnershipnegativeNegative

AI Analysis

Summary

BMS terminated its partnership with Cellares due to production problems with the automated platform used to manufacture an approved CAR-T cell therapy, resulting in layoffs. The setback represents a significant operational challenge for both companies' cell therapy manufacturing efforts.

Outcome Details

BMS terminated partnership with Cellares due to manufacturing problems with automated platform for CAR-T cell therapy production

Importance:6/10

Sentiment:

-0.75

partnership terminationmanufacturing setbackCAR-T therapylayoffscell therapy

Related Companies

$BMY

Read the original article

Published by BioSpace on August 26, 2026 12:43 PM

Read Original